| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/18/2009 | US20090156568 Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| 06/18/2009 | US20090156566 Method of treating middle ear infections |
| 06/18/2009 | US20090156564 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
| 06/18/2009 | US20090156558 Phosphonate analogs of antimetabolites |
| 06/18/2009 | US20090156528 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/18/2009 | US20090156507 Cell permeable conjugates of peptides for inhibition of protein kinases |
| 06/18/2009 | US20090156505 Self-assembly and mineralization of peptide-amphiphile nanofibers |
| 06/18/2009 | US20090156464 Pharmaceutical Compositions and Methods for Insulin Treatment |
| 06/18/2009 | US20090156463 Photokinetic delivery of biologically active substances using pulsed incoherent light |
| 06/18/2009 | US20090156460 Cationic betaine precursors to zwitterionic betaines having controlled biological properties |
| 06/18/2009 | US20090155897 Glycoprotein vi fusion proteins |
| 06/18/2009 | US20090155375 Compositions comprising a lipid and copolymer of styrene and maleic acid |
| 06/18/2009 | US20090155372 Method of manufacturing modified release dosage forms |
| 06/18/2009 | US20090155363 Methods for oral administration of active drugs |
| 06/18/2009 | US20090155356 Thixotropic oil based vehicle for pharmaceutical compositions |
| 06/18/2009 | US20090155346 Preparation of powders containing colloidal particles |
| 06/18/2009 | US20090155326 Layered drug delivery polymer monofilament fibers |
| 06/18/2009 | US20090155325 Formulation and products for promoting skin cleanliness and health |
| 06/18/2009 | US20090155309 Novel vaccine |
| 06/18/2009 | US20090155302 Antigen Arrays for Treatment of Allergic Eosinophilic Diseases |
| 06/18/2009 | US20090155282 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 06/18/2009 | US20090155235 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| 06/18/2009 | US20090155195 Capsules |
| 06/18/2009 | US20090155193 Topical Bioadhesive Formulations |
| 06/18/2009 | US20090155178 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 06/18/2009 | US20090155177 Phthalocyanine dyes and their preparation and use |
| 06/18/2009 | DE102007060175A1 Quartärnisierung des Zusatzstoffs Aminoalkyl Methacrylat Copolymer E zur Verbesserung der Permeabilität und Löslichkeit von Arzneistoffen Quaternization of aminoalkyl methacrylate copolymer E additive to improve the permeability and solubility of drugs |
| 06/18/2009 | CA2708762A1 Formulation of insulinotropic peptide conjugates |
| 06/18/2009 | CA2708719A1 High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles |
| 06/18/2009 | CA2708431A1 Quaternization of the additive aminoalkyl methacrylate copolymer e for improving permeability and solubility of pharmaceuticals |
| 06/18/2009 | CA2708234A1 Aqueous loxoprofen-containing patches |
| 06/18/2009 | CA2708233A1 Tape preparation comprising etodolac in ionic liquid form |
| 06/17/2009 | EP2070970A2 Transfection Reagent |
| 06/17/2009 | EP2070968A2 Method for the Preparation of 1-Benzotriazolyl Carbonate Esters of Poly(ethylene glycol) |
| 06/17/2009 | EP2070951A1 Method for producing a hydroxyalkyl starch derivatives with two linkers |
| 06/17/2009 | EP2070950A1 Hydroxyalkyl starch derivatives and process for their preparation |
| 06/17/2009 | EP2070947A1 Therapeutic and diagnostic anti-Hsp70 antibodies |
| 06/17/2009 | EP2070917A1 Taste-improving agent and food or drink containing the same |
| 06/17/2009 | EP2070551A1 Improved thickened beverages for dysphagia |
| 06/17/2009 | EP2070539A1 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine |
| 06/17/2009 | EP2070518A2 Ophthalmic solutions |
| 06/17/2009 | EP2070517A2 Pharmaceutical composition and method for treating hypogonadism |
| 06/17/2009 | EP2069413A1 Comb polymers and use thereof for the production of active or effective ingredient formulations |
| 06/17/2009 | EP2068936A2 Means and methods of enhancing delivery to biological systems |
| 06/17/2009 | EP2068935A1 Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1 |
| 06/17/2009 | EP2068934A2 Formulations comprising cyclic compounds |
| 06/17/2009 | EP2068933A2 Pharmaceutical compositions of clonazepam and methods of use thereof |
| 06/17/2009 | EP2068909A2 Modified fgf-21 polypeptides and their uses |
| 06/17/2009 | EP2068907A2 Glycerol linked pegylated sugars and glycopeptides |
| 06/17/2009 | EP2068893A2 Liquid chalcogenide compositions and methods of manufacturing and using the same |
| 06/17/2009 | EP2068885A1 Vitamin d compositions and method of administration to a human being |
| 06/17/2009 | EP2068876A2 Aqueous formulation comprising an antitumor agent |
| 06/17/2009 | EP2068852A1 Antiviral compositions and use thereof |
| 06/17/2009 | EP2068844A2 Programmable buoyant delivery technology |
| 06/17/2009 | EP2068836A2 Dry powder compound formulations and uses thereof |
| 06/17/2009 | EP2068834A2 Stable powder formulations of aluma-dsorbed vaccines |
| 06/17/2009 | EP2068833A2 Parenteral preparations of gi-safer phospholipid-associated anti-inflammatories and methods of preparation and use |
| 06/17/2009 | EP2068829A2 Semi-solid formulations of phospholipase enzyme inhibitors |
| 06/17/2009 | EP2068828A2 Biodegradable ocular implants and methods for treating ocular conditions |
| 06/17/2009 | EP2068822A2 Self preserved aqueous pharmaceutical compositions |
| 06/17/2009 | EP2068821A2 Ophthalmic pharmaceutical compositions and uses thereof |
| 06/17/2009 | EP1790654B1 Peptide capable of binding to insulin-binding protein and adsorbent |
| 06/17/2009 | EP1786468B1 Composition for promoting vascular smooth muscle relaxation |
| 06/17/2009 | EP1745078B1 Method for the purification of albumin conjugates |
| 06/17/2009 | EP1648933B1 Long lasting insulin derivatives and methods thereof |
| 06/17/2009 | EP1579506A4 Water soluble metal and semiconductor nanoparticle complexes |
| 06/17/2009 | EP1527341B1 Interfacial biomaterials |
| 06/17/2009 | EP1491204B1 Process for producing fat composition containing hydrophobic components of glycyrrhiza |
| 06/17/2009 | EP1465652A4 Povidone-containing carriers for polypeptide growth factors |
| 06/17/2009 | EP1015496B1 Divalent anti-t cells immunotoxins and use thereof |
| 06/17/2009 | EP1004310B1 Gelled composition |
| 06/17/2009 | EP0947196B1 Sustained-release prostaglandin i derivative preparation |
| 06/17/2009 | CN101460198A Thermosensitive polyphosphazene-bioactive molecule conjugates, preparation method thereof and use thereof |
| 06/17/2009 | CN101455845A PEG-decorated phospholipid derivative using octreotide as target ligand and production method thereof |
| 06/17/2009 | CN101455844A PEG-erythrocyte-stimulating factor and preparation method and use thereof |
| 06/17/2009 | CN101455843A Cisplatin polymer micelle preparation method and use thereof |
| 06/17/2009 | CN101455649A Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein |
| 06/17/2009 | CN100500221C Bioerodible film for ophthalmic drug delivery |
| 06/17/2009 | CN100500211C Methods of therapy with thrombin derived peptides |
| 06/17/2009 | CN100500200C Fuyankang pills against gynecologic inflammation and their preparation |
| 06/17/2009 | CN100500162C Anti-coronavirus agent |
| 06/17/2009 | CN100500157C Water-soluble medicine slow release tablet and its preparation method |
| 06/17/2009 | CN100500148C A buffered, liquid nicotine composition for pulmonary administration |
| 06/17/2009 | CN100500147C New formulations and use thereof |
| 06/17/2009 | CN100500140C Dermal compositions containing coenzyme Q as active ingredient |
| 06/17/2009 | CN100500137C Film coating for tablets and caplets |
| 06/16/2009 | US7547765 For modifying polypeptides; shikimic acid, quinic acid, or carbohydrate derivatives of polyalkylene glycols; improves bioavailability of modified peptides such as enzyme, a cytokine or a hormone e.g. interferon beta or granulocyte colony stimulating factor; biodrugs |
| 06/16/2009 | US7547527 Use of probiotic lactic acid bacteria for balancing the skin's immune system |
| 06/16/2009 | US7547452 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| 06/16/2009 | US7547451 Comprises core and enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a derivative thereof; treatment of ulcerative colitis and Crohn's disease |
| 06/16/2009 | US7547443 Skin care topical ointment |
| 06/16/2009 | US7547436 Receptor specific transepithelial transport of therapeutics |
| 06/16/2009 | US7547433 Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
| 06/16/2009 | CA2476934C Stabilized tnfr-fc composition comprising arginine |
| 06/16/2009 | CA2439813C Porous beta-tricalcium phosphate granules and methods for producing same |
| 06/16/2009 | CA2396180C Stable aqueous deoxyfructosazine solution |
| 06/16/2009 | CA2386762C Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| 06/16/2009 | CA2382540C High viscosity liquid composition for the delivery of substances |
| 06/16/2009 | CA2361936C Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
| 06/16/2009 | CA2347097C Process for purification of solvents useful in the preparation of pharmaceutical compositions |